Morgan Stanley Initiates Depomed With Equal-weight

Analysts at Morgan Stanley initiated coverage on

with a Equal-weight rating. The target price for Depomed is set to $23. Depomed shares have gained 60.41 percent over the past 52 weeks, while the S&P 500 index has surged 9.07 percent in the same period. Depomed shares fell 1.35 percent to close at $21.19 yesterday.